KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Accumulated Expenses: 2016-2025

Historic Other Accumulated Expenses for Ionis Pharmaceuticals (IONS) over the last 3 years, with Sep 2025 value amounting to $24.8 million.

  • Ionis Pharmaceuticals' Other Accumulated Expenses rose 12.44% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 12.44%. This contributed to the annual value of $19.5 million for FY2024, which is 34.25% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Other Accumulated Expenses of $24.8 million as of Q3 2025, which was up 8.76% from $22.8 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $29.6 million for Q4 2023, and its period low was $9.6 million during Q1 2023.
  • For the 3-year period, Ionis Pharmaceuticals' Other Accumulated Expenses averaged around $19.2 million, with its median value being $19.5 million (2024).
  • In the last 5 years, Ionis Pharmaceuticals' Other Accumulated Expenses slumped by 60.10% in 2021 and then spiked by 142.65% in 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $12.3 million in 2021, then decreased by 0.95% to $12.2 million in 2022, then spiked by 142.65% to $29.6 million in 2023, then crashed by 34.25% to $19.5 million in 2024, then rose by 12.44% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, $22.8 million for Q2 2025, and $22.3 million during Q1 2025.